22.728 articles found

Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease.

Ebihara K, Ishida Y, Takeda R, Abe H, Matsuo H, Kawai K, Magata Y, Nishimori T.

Neurosci Lett · 2011-04-12

DOI: 10.1016/j.neulet.2011.03.087PMID: 21507338

Motor complications, levodopa metabolism and progression of Parkinson's disease.

Müller T.

Expert Opin Drug Metab Toxicol · 2011-04-12

DOI: 10.1517/17425255.2011.575779PMID: 21480824

IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING ELECTRODES WITH MICROVOLTAMMETRY

BRODERICK PATRICIA A, PACIA STEVEN V.

· 2011-04-11

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B.

Mov Disord · 2011-04-11

DOI: 10.1002/mds.23616PMID: 21484867

Drug and treatment costs in Parkinson's disease patients in Sweden.

Lökk J, Borg S, Svensson J, Persson U, Ljunggren G.

Acta Neurol Scand · 2011-04-06

DOI: 10.1111/j.1600-0404.2011.01517.xPMID: 21470194

Therapeutic applications of antibodies in non-infectious neurodegenerative diseases.

Krishnamurthy PK, Sigurdsson EM.

N Biotechnol · 2011-04-05

DOI: 10.1016/j.nbt.2011.03.020PMID: 21473943

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM.

Mov Disord · 2011-04-04

DOI: 10.1002/mds.23631PMID: 21465551

GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the Hemi-Parkinsonian rat.

Ba M, Kong M, Yu G, Sun X, Liu Z, Wang X.

Neurochem Res · 2011-04-03

DOI: 10.1007/s11064-011-0461-yPMID: 21461922

Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.

Hicks CW, Pandya MM, Itin I, Fernandez HH.

Parkinsonism Relat Disord · 2011-04-02

DOI: 10.1016/j.parkreldis.2011.03.003PMID: 21459656

Dramatic response of dropped head sign to treatment with steroid in Parkinson's disease: report of three cases.

Hemmi S, Kurokawa K, Izawa N, Kutoku Y, Murakami T, Sunada Y.

Intern Med · 2011-04-01

DOI: 10.2169/internalmedicine.50.4395PMID: 21467712

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A.

Lancet Neurol · 2011-04-01

DOI: 10.1016/s1474-4422(11)70039-4PMID: 21419704

At last, a gene therapy for Parkinson's disease?

Hutchinson M.

Lancet Neurol · 2011-04-01

DOI: 10.1016/s1474-4422(11)70041-2PMID: 21419705